GH1 and cancer: Finally, an older phase III clinical trial (NCT00033605) published in 2008 investigated the utility of octreotide, a somatostatin analog able to inhibit GH, in reducing diarrhea in patients undergoing pelvic radiation as treatment of various cancers, including EC [121].